^
    11ms
    Very promising activity observed with BCA101 + pembro in p16 negative cps 1-19% 1st line R/M HNSCC. Exceptional presentation by @HeadNeckMD at #ASCO23 (@AhernandoCalvo)
    CDKN2A negative
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)
    2years
    Urothelial carcinoma, microcystic subtype. Almost becoming tubular morphology (described before). IHC GATA3 and KRT7. p63 positive, PAX8/CDX2/p16 negative. #gupath @Williamson_SR @LiangChengMD @GladellPaner @rovingatuscap (@AkgulMd)
    KRT7 (Keratin-7) • CDX2 (Caudal Type Homeobox 2) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
    |
    CDKN2A negative • PAX8 positive
    2years
    Genetic restoration of p16ink4A suppresses mesothelioma in preclinical models, underpinning the rationale for targeting CDK4 and CDK6 in p16ink4A-negative mesothelioma. We developed a multicentre, stratified, phase 2 trial to test this hypothesis 3/5 (@VivekSubbiah)
    P2 data
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    CDKN2A negative
    2years
    This study met its primary endpoint, showing promising clinical activity of abemaciclib in patients with p16ink4A-negative mesothelioma who were previously treated with chemotherapy, and warrants its further investigation in a randomised study as a targeted stratified therapy 5/5 (@VivekSubbiah)
    Clinical
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A negative
    |
    Verzenio (abemaciclib)